Bernard Chevalier

Summary

Publications

  1. ncbi request reprint Effect of a closure device on complication rates in high-local-risk patients: results of a randomized multicenter trial
    Bernard Chevalier
    Centre Cardiologique du Nord, Saint Denis, France
    Catheter Cardiovasc Interv 58:285-91. 2003
  2. ncbi request reprint Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter
    Bernard Chevalier
    Department of Cardiology, Centre Cardiologique du Nord, Saint Denis, France
    EuroIntervention 4:222-8. 2008
  3. doi request reprint Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2
    Bernard Chevalier
    Institut Cardiovasculaire Paris Sud, Massy Quincy, France
    Circ Cardiovasc Interv 2:188-95. 2009
  4. doi request reprint Is EuroSCORE II better than EuroSCORE in predicting mortality after transcatheter aortic valve implantation?
    Yusuke Watanabe
    Interventional Cardiology, Institut Cardiovasculaire Paris Sud, Massy, France
    Catheter Cardiovasc Interv 81:1053-60. 2013
  5. doi request reprint Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    Circ Cardiovasc Interv 6:284-91. 2013
  6. ncbi request reprint Potential mechanism of annulus rupture during transcatheter aortic valve implantation
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, 91300 Massy, France
    Catheter Cardiovasc Interv 82:E742-6. 2013
  7. doi request reprint Impact of post-procedural aortic regurgitation on mortality after transcatheter aortic valve implantation
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    JACC Cardiovasc Interv 5:1247-56. 2012
  8. doi request reprint Impact of CT-guided valve sizing on post-procedural aortic regurgitation in transcatheter aortic valve implantation
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    EuroIntervention 8:546-55. 2012
  9. doi request reprint Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    J Am Coll Cardiol 59:566-71. 2012
  10. doi request reprint Transfemoral aortic valve implantation new criteria to predict vascular complications
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    JACC Cardiovasc Interv 4:851-8. 2011

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Effect of a closure device on complication rates in high-local-risk patients: results of a randomized multicenter trial
    Bernard Chevalier
    Centre Cardiologique du Nord, Saint Denis, France
    Catheter Cardiovasc Interv 58:285-91. 2003
    ....
  2. ncbi request reprint Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter
    Bernard Chevalier
    Department of Cardiology, Centre Cardiologique du Nord, Saint Denis, France
    EuroIntervention 4:222-8. 2008
    ..It is unclear whether primary aspiration can prevent distal embolisation and thereby improve myocardial perfusion in patients presenting with acute myocardial infarction (AMI) within 12 hours after onset...
  3. doi request reprint Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2
    Bernard Chevalier
    Institut Cardiovasculaire Paris Sud, Massy Quincy, France
    Circ Cardiovasc Interv 2:188-95. 2009
    ..The newly developed Nobori coronary stent coated with a bioresorbable polymer, polylactic acid, and the antiproliferative agent Biolimus A9 has the potential to reduce restenosis by suppressing neointima formation...
  4. doi request reprint Is EuroSCORE II better than EuroSCORE in predicting mortality after transcatheter aortic valve implantation?
    Yusuke Watanabe
    Interventional Cardiology, Institut Cardiovasculaire Paris Sud, Massy, France
    Catheter Cardiovasc Interv 81:1053-60. 2013
    ..The purpose of this study was to examine the performance of the European system for cardiac operative risk evaluation II (ESII) in patients undergoing transcatheter aortic valve implantation (TAVI)...
  5. doi request reprint Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    Circ Cardiovasc Interv 6:284-91. 2013
    ..The purpose of this study was to evaluate the efficacy and safety of transcatheter aortic valve implantation in patients with BAV...
  6. ncbi request reprint Potential mechanism of annulus rupture during transcatheter aortic valve implantation
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, 91300 Massy, France
    Catheter Cardiovasc Interv 82:E742-6. 2013
    ..In both cases, annulus rupture occurred after deployment of a balloon expandable valve suggesting that mechanical compression of this "vulnerable area" by calcification may cause annulus rupture...
  7. doi request reprint Impact of post-procedural aortic regurgitation on mortality after transcatheter aortic valve implantation
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    JACC Cardiovasc Interv 5:1247-56. 2012
    ..The goal of the study was to clarify the impact of post-procedural aortic regurgitation (post-AR) grade 2/4 on clinical outcomes...
  8. doi request reprint Impact of CT-guided valve sizing on post-procedural aortic regurgitation in transcatheter aortic valve implantation
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    EuroIntervention 8:546-55. 2012
    ..However, computed tomography (CT) has potential advantages compared to TEE. We sought to assess the impact of CT-guided valve sizing on post-procedural aortic regurgitation (AR)...
  9. doi request reprint Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    J Am Coll Cardiol 59:566-71. 2012
    ..The purpose of this study was to clarify the impact of sex-related differences in transcatheter aortic valve implantation (TAVI) for high-risk patients with severe aortic stenosis...
  10. doi request reprint Transfemoral aortic valve implantation new criteria to predict vascular complications
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    JACC Cardiovasc Interv 4:851-8. 2011
    ..This study sought to evaluate the incidence, impact, and predictors of vascular complications in transcatheter aortic valve implantation (TAVI)...
  11. doi request reprint True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications
    Kentaro Hayashida
    Institut Cardiovasculaire Paris Sud, Massy, France
    JACC Cardiovasc Interv 5:207-14. 2012
    ..The purpose of this study was to evaluate the incidence of vascular complications and the predictors of Prostar failure for a "true percutaneous approach" in transfemoral transcatheter aortic valve implantation (TAVI)...
  12. doi request reprint Transfemoral aortic valve implantation in patients with an annulus dimension suitable for either the Edwards valve or the CoreValve
    Yusuke Watanabe
    Institut Cardiovasculaire Paris Sud, Massy, France
    Am J Cardiol 112:707-13. 2013
    ..31). In conclusion, in patients with annulus of intermediate size, similar device success and short-term and midterm outcomes were achieved with either of the valves, irrespective of the specific complications related to each valve...
  13. doi request reprint A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial
    Bernard Chevalier
    Centre Cardiologique du Nord, Saint Denis, France
    JACC Cardiovasc Interv 1:524-32. 2008
    ..The primary end point was defined as noninferiority of in-segment late lumen loss after 9 months...
  14. ncbi request reprint The transaortic approach for transcatheter aortic valve implantation: a valid alternative to the transapical access in patients with no peripheral vascular option. A single center experience
    Kentaro Hayashida
    Department of Interventional Cardiology, Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques Cartier, Massy, France
    Eur J Cardiothorac Surg 44:692-700. 2013
    ..The purpose of this study was to evaluate the efficacy and safety of the TAo-TAVI approach using both the Sapien XT and the CoreValve according to VARC criteria...
  15. ncbi request reprint Transcatheter aortic valve implantation in patients of small body size
    Yusuke Watanabe
    Institut Cardiovasculaire Paris Sud, 6 avenue du Noyer Lambert, 91300, Massy, France
    Catheter Cardiovasc Interv 84:272-80. 2014
    ..The aim of this study was to evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) in patients of small body size (SB)...
  16. ncbi request reprint One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents
    Bernard Chevalier
    Institut Cardiovasculaire Paris Sud, Massy, France
    J Interv Cardiol 25:586-95. 2012
    ....
  17. ncbi request reprint Stenting of bifurcation lesions using the Bestent: a prospective dual-center study
    Francois Gobeil
    Institut Cardiovasculaire Paris Sud, Massy, France
    Catheter Cardiovasc Interv 55:427-33. 2002
    ....
  18. ncbi request reprint Duration of balloon inflation for optimal stent deployment: five seconds is not enough
    Thomas Hovasse
    Department of Interventional Cardiology, Institut Hospitalier Jacques Cartier, Massy, France
    Catheter Cardiovasc Interv 81:446-53. 2013
    ..To assess the effect of the duration of stent inflation on stent expansion using digital stent enhancement (DSE)...
  19. ncbi request reprint Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial
    Bernard Chevalier
    Centre Cardiologique du Nord, Saint Denis, France
    EuroIntervention 2:426-34. 2007
    ..Conclusions: In this trial the Nobori Biolimus A9 eluting stent proved to be safe and effective in reducing neointimal proliferation. The long term safety remains to be confirmed during the extended follow-up period of 5 years...
  20. ncbi request reprint Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registr
    Anouska Moynagh
    Institut Jacques Cartier and Hopital Claude Galien, Institut Cardiovasculaire Paris Sud, Massy and Quincy, France
    EuroIntervention 9:452-62. 2013
    ..Using data from the French Left Main Taxus and the LEft MAin Xience registries, we compared two-year outcomes in consecutive patients from 2003-2008 using everolimus-eluting stents (EES) vs. paclitaxel-eluting stents (PES)...
  21. doi request reprint [Percutaneous aortic valve implantation: results and perspectives]
    Thomas Hovasse
    Hôpital privé Jacques Cartier, Institut Cardiovasculaire Paris Sud, 91300 Massy, France
    Presse Med 40:732-9. 2011
    ..This new approach is clearly here to stay and should soon reach a maturity phase with respect to its indications, the selection of patients and technical aspects...
  22. ncbi request reprint Saphenous vein graft stenting using a novel filter device for distal protection
    Michael Schlüter
    Center for Cardiology and Vascular Intervention, Hamburg, Germany
    Am J Cardiol 91:736-9. 2003
  23. ncbi request reprint Effectiveness of "direct" stenting without balloon predilatation (from the Multilink Tetra Randomised European Direct Stent Study [TRENDS])
    Keith D Dawkins
    The Southampton University Hospital, Southampton, United Kingdom
    Am J Cardiol 97:316-21. 2006
    ....
  24. ncbi request reprint Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials)
    Grzegorz L Kałuza
    The Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 94:199-201. 2004
    ..05). Also, significantly shorter lesion lengths at 6-month follow-up were observed for the doses of 0.7 to 3.1 microg/mm(2) (p <0.03) relative to their respective lengths before the procedure compared with control stents...
  25. ncbi request reprint Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris
    Campbell Rogers
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:1735-40. 2004
    ..We used a novel method of microparticle size assessment to measure volume and characterize individual sizes of particles captured by the PercuSurge GuardWire balloon or a vascular filter during saphenous vein graft stenting...
  26. ncbi request reprint Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial
    Anthony Gershlick
    Department of Cardiology, University Hospitals of Leicester, Glenfield Hospital, Leicester, UK
    Circulation 109:487-93. 2004
    ..The use of a stent to deliver a drug may reduce in-stent restenosis. Paclitaxel interrupts the smooth muscle cell cycle by stabilizing microtubules, thereby arresting mitosis...